Search for Studies
Search Results
Wrist fractures are the most prevalent adult fracture. Complex regional pain syndrome (CRPS) is a common complication that can occur, leading to permanent disability and is costly to the patient and healthcare system. In addition, amidst the opioid epidemic, the risk of increased opioid use in patients with CRPS prompts the need to find viable treatment strategies. This study aims to evaluate an anti-inflammatory medication, prednisone, in the early treatment of CRPS. Patients with wrist fractures who undergo surgical treatment will be randomized to receiving placebo vs prednisone for 2 weeks. Clinical assessments in the follow up period will be compared.
Conditions:
Complex Regional Pain Syndromes | Distal Radius FracturesLocation:
- Vancouver General Hospital, Vancouver, British Columbia, Canada
Sex:
ALLAges:
Over 19Background: Chemotherapy treatment (CT) can have burdensome side effects such as fatigue, nausea-vomiting, and sleep problems that can significantly affect patients' quality of life. Fatigue is the most common, lasting and bothersome of these, which prevents people from working and carrying out daily activities. Mindfulness-Based Cancer Recovery (MBCR) is an evidence-based group training program which has shown to help treat negative physical and psychosocial symptoms in cancer patients. The investigators propose to evaluate a pilot-tested online-MBCR program for patients undergoing CT who may be low on energy, time or have compromised immunity. Objectives: To evaluate the impact of participation in online MBCR during CT on fatigue (primary outcome), sleep, pain, nausea/vomiting, mood disturbance, stress symptoms and quality of life (secondary outcomes) as well as cognitive function and return to work (exploratory outcomes) over the course of treatment. Methods: The study design is a randomized wait-list controlled trial, conducted during CT for patients with breast or colorectal cancer. Participants will take the 12-week online MBCR program at home within 2 weeks of randomization (immediate group) or after CT completion (waitlist group). Outcomes will be assessed online at, 1) Baseline, 2) Post-MBCR, 3) Post-CT (primary outcome) and 4) 12 months post-baseline. Anticipated Findings: MBCR is a promising adjuvant program that could help patients prevent, delay or diminish aversive symptoms and side-effects associated with CT, particularly fatigue. If helpful, online-MBCR could be made easily available at cancer centers worldwide and significantly lessen the burden of cancer treatments.
Conditions:
Colorectal Cancer | Breast Cancer | Chemotherapy EffectLocation:
- University of Calgary, Calgary, Alberta, Canada
Sex:
ALLAges:
Over 18Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). This new Linac-MR is a unique innovation at the Cross Cancer Institute, with theoretical advantages over other Linac-MR machines that are being tested elsewhere in the world. This feasibility study is being done as a first step in clinical development of the Linac-MR, as this new technology has to be tested to see if it is acceptable to both doctors and participants. The purpose of this Phase I/II study is (1) to verify treatment completion as intended and scheduled the oncology team, and (2) to evaluate treatment effects, including any expected or unexpected radiation side effects and cancer response to radiation. This study will allow the researchers at the Cross Cancer Institute to develop this technology further by conducting additional studies to take advantage of MRI scanning on tumor tracking during radiation treatments.
Conditions:
CancerLocation:
- Cross Cancer Institute, Edmonton, Alberta, Canada
Sex:
ALLAges:
Over 18Developmental dysplasia of the hip (DDH) is the most common childhood hip condition. When caught early, bracing is the most frequently used treatment; however, the brace can disrupt important mother-baby bonding time in the newborn period and present challenges to daily living. In babies with mild DDH, some studies have suggested that their hips may improve naturally as they grow and develop. This study will look at whether careful monitoring can be just as good as bracing for babies diagnosed with mild DDH less than 3 months of age, potentially avoiding unnecessary treatment. This will be the first study to look at this question with babies being treated at different hospitals in seven different countries, so the results will make an impact on children and families worldwide.
Conditions:
Hip Dysplasia | Developmental Dysplasia of the Hip | Hip Dysplasia, Congenital | Hip Dysplasia, DevelopmentalLocation:
- BC Children's Hospital, Vancouver, British Columbia, Canada
Sex:
ALLAges:
Under 12This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
Conditions:
Aortic Stenosis | Aortic Valve StenosisLocation:
- CRIUCPQ, Québec, Quebec, Canada
Sex:
ALLAges:
20 - 99To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of treatment.
Conditions:
Mycobacterium Avium Complex Pulmonary DiseaseLocation:
- University of Calgary, Calgary, Alberta, Canada
Sex:
ALLAges:
Over 18The purpose of this study is to develop and evaluate a Magnetic Resonance (MR) fusion 3D Ultrasound (US) guided Low dose rate (LDR) brachytherapy technique that significantly spares prostatic neurovascular bundles (a bundle of nerves and vessels that run beside the prostate) and penile bulb (base of the penis), while still trying to effectively treat the prostate cancer.
Conditions:
Prostate CancerLocation:
- London Regional Cancer Program, London, Ontario, Canada
Sex:
MALEAges:
18 - 75The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months). The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
Conditions:
Chronic Rhinosinusitis With Nasal Polyps | Olfactory DisorderLocation:
- St. Joseph's Health Care, London, Ontario, Canada
Sex:
ALLAges:
Over 18Patients with head and neck cancer typically undergo a surgical procedure to remove the lymph nodes that could contain disease on both sides of the neck. After surgery, radiotherapy is given (with or without chemotherapy) to the area that underwent surgery and both sides of the neck, even if disease was only found on one side. Giving radiotherapy to both sides of the neck commonly results in high rates of side effects, which in turn affects patient quality of life. There is growing evidence from some other studies that support the safety of omitting radiotherapy after surgery in the side of the neck with no disease. With this study, the investigators are hoping to justify its routine use and, if successful, the standard of care could be to receive radiation on only one side of the neck instead of both sides. This could alleviate the extent of some side effects and improve patient quality of life. Participants will be randomized into one of the following groups to receive radiotherapy as follows: Arm 1 (Non-experimental intervention): standard intervention: Radiotherapy to both sides of the neck. Treatment will begin a maximum of 8 weeks from the surgery date. Arm 2 (Experimental intervention): Radiotherapy to one side of the neck. Treatment will begin a maximum of 8 weeks from the surgery date.
Conditions:
Head and Neck NeoplasmsLocation:
- Cross Cancer Institute, Edmonton, Alberta, Canada
Sex:
ALLAges:
Over 18The primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to conventional fractionation to the breast or chest wall and regional nodes delivered over 3 weeks (40Gy in 15 daily fractions) in patients with node-positive breast cancer.
Conditions:
Breast Neoplasms | Lymphedema | RadiotherapyLocation:
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BC Cancer - Vancouver Island Centre, Victoria, British Columbia, Canada
- Northeast Cancer Centre, Health Sciences North, Sudbury, Ontario, Canada
- CIUSSS de l'Est-de-l'Île de Montréal, Hôpital, Maisonneuve-Rosemont, Montreal, Quebec, Canada
- Sherbrooke University Hospital Centre, Sherbrooke, Quebec, Canada
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- BC Cancer - Vancouver Centre, Vancouver, British Columbia, Canada
- The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
- Hotel-Dieu de Lévis (CISSS CA), Lévis, Quebec, Canada
- CHU-de Québec-Université de Laval, Quebec City, Quebec, Canada
- BC Cancer - Centre for the Southern Interior, Kelowna, British Columbia, Canada
- Juravinski Cancer Centre, Hamilton, Ontario, Canada
- Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, Ontario, Canada
- McGill University Health Centre-Cedars Cancer Centre, Montréal, Quebec, Canada
- Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
- BC Cancer - Centre for the North, Prince George, British Columbia, Canada
- London Regional Cancer Program, London, Ontario, Canada
- Princess Margaret Cancer Centre - UHN, Toronto, Ontario, Canada
- CHUM - Centre Hospitalier de L'Universite de Montreal, Montréal, Quebec, Canada
- Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada